Search
Home
About FERRLECIT
Iron Deficiency Anemia
Professional Resource Center
Ferrlecit Support Programs
Dosing Reimbursment
Request a Rep/Order Reprints
Contact Us
Full Prescribing Information
Active Iron Management
The Drive Study
 
Defining Iron Deficiency
 
The percent transferrin saturation (TSAT) and serum ferritin (SF) are indirect measures of iron status and are at present the two most commonly used tests to diagnose absolute and functional iron deficiency in patients with chronic kidney disease.

Absolute iron deficiency may be diagnosed when TSAT is <20% and SF is <100 ng/mL for patients with chronic kidney disease.[5]

Functional iron deficiency may be more difficult to diagnose since iron status parameters may indicate adequate iron stores. Patients on epoetin with functional iron deficiency have TSAT <20% and normal serum ferritin levels (≥100 ng/mL) but experience hemoglobin or hematocrit decreases at the same or an increased epoetin dose. Patients with functional iron deficiency may experience an increase in hemoglobin/hematocrit after a course of IV iron therapy.

Functional iron deficiency also must be differentiated from inflammatory iron block, which can also occur in patients with chronic inflammatory conditions such as infections, certain malignancies, and autoimmune disorders. In this case, both hemoglobin and hematocrit are reduced, and TSAT may be <20%.[5] SF levels, on the other hand, may be 100 to 700 ng/mL or higher. In patients with functional iron deficiency, serial levels of SF decrease during epoetin alfa therapy, yet remain elevated (≥100 ng/mL); in contrast, patients with inflammatory iron block usually show an abrupt increase in SF along with a sudden drop in TSAT.[5]

 
Link to Algorithm
 
 
+ References:
 
Safety Information
FERRLECIT is contraindicated in non iron-deficient anemias, in patients hypersensitive to FERRLECIT or its inactive components, or with evidence of iron overload • Hypersensitivity reactions have been reported with injectable iron products • Hypotension has been reported with rapid administration of IV iron • In a single-dose, placebo-controlled safety study (n=1097), the most frequent adverse events occurring after FERRLECIT administration were hypotension, nausea, and vomiting and/or diarrhea • In multiple-dose studies (n=126), the most frequent adverse events, whether or not related to FERRLECIT administration, were nausea, vomiting and/or diarrhea, injection site pain, hypotension, cramps, hypertension, dizziness, dyspnea, and chest pain • Please see full prescribing information for Warnings, Precautions, and Adverse Reactions
Watson Pharmaceuticals, Inc.